The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Factors associated with treatment duration from start of second-line ramucirumab plus paclitaxel or nab-PTX for advanced gastric cancer: real-world evidence from Japanese Claim Database.
 
Shuichi Hironaka
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck; Nihonkayaku; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Tsumura & Co.; Yakult Honsha
Consulting or Advisory Role - AstraZeneca; MSD K.K; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Kyowa Hakko Kirin (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Yakult Honsha (Inst); Yakult Honsha (Inst)
 
Yoshito Komatsu
Honoraria - Asahi Kasei; Bayer Yakuhin; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Medical Review Co., Ltd.; Merck; Mitsubishi Tanabe Pharma; Moroo Co.; Nipro Corporation; Ono Pharmaceutical; Otsuka; Sanofi/Aventis; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - A2 Healthcare; Astellas Pharma; Bayer Yakuhin; BeiGene (Inst); Daiichi Sankyo; Eisai; Incyte; IQvia; Lilly (Inst); Mediscience Planning; Merck Sharp & Dohme; NanoCarrier; Nipro Corporation (Inst); Ono Pharmaceutical; Parexel International Corporation.; Sanofi/Aventis; Shionogi; Sumitomo Dainippon; Sysmex; Taiho Pharmaceutical; Yakult Honsha
 
Yoshinori Tanizawa
Employment - Lilly Japan
Stock and Other Ownership Interests - Lilly
 
Zhihong Cai
Employment - Lilly Japan
Stock and Other Ownership Interests - Lilly
 
Yongzhe Piao
Employment - Lilly Japan
Stock and Other Ownership Interests - Lilly
 
Narikazu Boku
Honoraria - Bristol-Myers Squibb Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst); Takeda (Inst)